Stevenson et al., 2008 - Google Patents
Effect of breeding protocols and reproductive tract score on reproductive performance of dairy heifers and economic outcome of breeding programsStevenson et al., 2008
View HTML- Document ID
- 11468129798752956227
- Author
- Stevenson J
- Rodrigues J
- Braga F
- Bitente S
- Dalton J
- Santos J
- Chebel R
- Publication year
- Publication venue
- Journal of dairy science
External Links
Snippet
The objectives of this study were to evaluate the effect of reproductive protocols and reproductive tract score on reproductive performance of dairy heifers and economic outcomes of breeding programs. Holstein heifers (n= 534), 13±1 mo of age, were randomly …
- 230000001850 reproductive 0 title abstract description 98
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stevenson et al. | Effect of breeding protocols and reproductive tract score on reproductive performance of dairy heifers and economic outcome of breeding programs | |
| Sá Filho et al. | Importance of estrus on pregnancy per insemination in suckled Bos indicus cows submitted to estradiol/progesterone-based timed insemination protocols | |
| Santos et al. | Effect of bST and reproductive management on reproductive performance of Holstein dairy cows | |
| Carvalho et al. | Manipulation of progesterone to increase ovulatory response to the first GnRH treatment of an Ovsynch protocol in lactating dairy cows receiving first timed artificial insemination | |
| Pereira et al. | Timed artificial insemination programs during the summer in lactating dairy cows: Comparison of the 5-d Cosynch protocol with an estrogen/progesterone-based protocol | |
| Rabaglino et al. | Application of one injection of prostaglandin F2α in the five-day Co-Synch+ CIDR protocol for estrous synchronization and resynchronization of dairy heifers | |
| Watters et al. | Effect of dry period length on reproduction during the subsequent lactation | |
| Chebel et al. | Effect of inseminating cows in estrus following a presynchronization protocol on reproductive and lactation performances | |
| Pereira et al. | Effect of adding a gonadotropin-releasing-hormone treatment at the beginning and a second prostaglandin F2α treatment at the end of an estradiol-based protocol for timed artificial insemination in lactating dairy cows during cool or hot seasons of the year | |
| Hashem et al. | Effect of GnRH treatment on ovarian activity and reproductive performance of low-prolific Rahmani ewes | |
| Rivera et al. | Use of intravaginal progesterone-releasing inserts in a synchronization protocol before timed AI and for synchronizing return to estrus in Holstein heifers | |
| Pereira et al. | Increasing length of an estradiol and progesterone timed artificial insemination protocol decreases pregnancy losses in lactating dairy cows | |
| Santos et al. | Adding a second prostaglandin F2α treatment to but not reducing the duration of a PRID-Synch protocol increases fertility after resynchronization of ovulation in lactating Holstein cows | |
| Nogueira et al. | Timed artificial insemination plus heat I: effect of estrus expression scores on pregnancy of cows subjected to progesterone–estradiol-based protocols | |
| Portaluppi et al. | Pregnancy rates in lactating dairy cows after presynchronization of estrous cycles and variations of the Ovsynch protocol | |
| Dirandeh et al. | Administration of prostaglandin F2α 14 d before initiating a G6G or a G7G timed artificial insemination protocol increased circulating progesterone prior to artificial insemination and reduced pregnancy loss in multiparous Holstein cows | |
| Stevenson et al. | Effect of synchronization protocols on follicular development and estradiol and progesterone concentrations of dairy heifers | |
| Keskin et al. | Effect of hCG vs. GnRH at the beginning of the Ovsynch on first ovulation and conception rates in cyclic lactating dairy cows | |
| Galvao et al. | Evaluation of methods of resynchronization for insemination in cows of unknown pregnancy status | |
| Rodrigues et al. | Effect of interval from induction of puberty to initiation of a timed AI protocol on pregnancy rate in Nellore heifers | |
| Miranda et al. | Estrus resynchronization in ewes with unknown pregnancy status | |
| Pfeifer et al. | Development and validation of an objective method for the assessment of body condition scores and selection of beef cows for timed artificial insemination | |
| Lopes Jr et al. | Evaluation of reproductive and economic outcomes of dairy heifers inseminated at induced estrus or at fixed time after a 5-day or 7-day progesterone insert-based ovulation synchronization protocol | |
| Motta et al. | Increased pregnancy rate in beef heifers resynchronized with estradiol at 14 days after TAI | |
| Stevenson et al. | Dose frequency of prostaglandin F2α administration to dairy cows exposed to presynchronization and either 5-or 7-day Ovsynch program durations: Ovulatory and luteolytic risks |